Compare
Avalo Therapeutics, Inc. vs Connect Biopharma Holdings Ltd vs HCW Biologics Inc. vs Incannex Healthcare Inc.
| Latest fiscal year | Avalo Therapeutics, Inc. AVTX | Connect Biopharma Holdings Ltd CNTB | HCW Biologics Inc. HCWB | Incannex Healthcare Inc. IXHL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-06-30 |
| Revenue | $59.0K | $64.0K | $54.2K | $86.0K |
| Revenue growth (YoY) | -86.6% | -99.8% | -97.9% | +616.7% |
| Gross margin | n/a | n/a | 20.0% | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$78.26M | -$55.48M | -$7.96M | -$46.88M |
| EPS (Diluted) | -$5.84 | -$1.00 | -$10.63 | -$1.35 |
| Operating cash flow | -$51.46M | -$51.21M | -$13.39M | -$12.51M |
| Free cash flow | n/a | -$51.64M | -$13.39M | -$12.52M |
| Cash & equivalents | $15.86M | $38.34M | $1.95M | $15.04M |
| Total assets | $116.46M | $56.08M | $24.52M | $20.45M |
| Total liabilities | $33.41M | $14.10M | $21.76M | $7.06M |
| Shareholders' equity | $83.05M | $41.98M | $2.76M | $13.39M |
| Return on year-end equity | -94.2% | -132.2% | -287.9% | -350.2% |
| Shares outstanding | 18.51M | 56.44M | n/a | 194.38M |
Revenue, most recent five fiscal years
| Fiscal year | Avalo Therapeutics, Inc. | Connect Biopharma Holdings Ltd | HCW Biologics Inc. | Incannex Healthcare Inc. |
|---|---|---|---|---|
| Latest | $59.0K Ended 2025-12-31 | $64.0K Ended 2025-12-31 | $54.2K Ended 2025-12-31 | $86.0K Ended 2025-06-30 |
| 1 year earlier | $441.0K Ended 2024-12-31 | $26.03M Ended 2024-12-31 | $2.57M Ended 2024-12-31 | $12.0K Ended 2024-06-30 |
| 2 years earlier | $1.92M Ended 2023-12-31 | $0 Ended 2023-12-31 | $2.84M Ended 2023-12-31 | n/a |
| 3 years earlier | $18.05M Ended 2022-12-31 | n/a | $6.72M Ended 2022-12-31 | n/a |
| 4 years earlier | $5.40M Ended 2021-12-31 | n/a | $0 Ended 2021-12-31 | n/a |